China’s Biopharma Firm Gan & Lee Teams Up With Novartis In Global Insulin Push

Login to View

Gan & Lee Pharmaceuticals, a biopharmaceutical company specializing in insulin and insulin analogues in China, announced that it has entered into an agreement to commercialize three insulin analogs to Sandoz, a division of Swiss drugmaker Novartis with a focus on biosimilar pharmaceuticals.

China Money Network

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech


Want to read this important story?

Access Over 11,000 stories and data posts over the past 8 years!

Register Now


Already have an account or paid subscription? Log in


RELATED NEWS